Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.44 |
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314686 | 0.93 | CNR2 (0.48) | CNR2CNR1IDH1TAS1R3TAS1R1 | |
| SCHEMBL5317181 | 0.91 | CNR2 (0.45) | CNR2CNR1IDH1TAS1R3TAS1R1 | |
| SCHEMBL5314891 | 0.90 | CNR2 (0.44) | CNR2CNR1HDAC1HDAC6IDH1 | |
| SCHEMBL5317320 | 0.88 | CNR2 (0.46) | CNR2CNR1TAS1R3TAS1R1DDB1 | |
| SCHEMBL10216961 | 0.83 | CNR2 (0.52) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL13871505 | 0.83 | CNR2 (0.52) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL13871431 | 0.81 | CNR2 (0.46) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL5317316 | 0.81 | CNR2 (0.41) | CNR2CNR1TAS1R3TAS1R1DDB1 | |
| SCHEMBL4881359 | 0.81 | CNR2 (0.45) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL5317196 | 0.81 | CNR2 (0.45) | CNR2CNR1HDAC1HDAC6TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-27 | — | — | US | claimed |
| EP-1804791-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006049880-A1 | TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089378-A1 | Tetrahydro-pyridinyl pyrazole cannabinoid modulators | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885HDAC1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.